Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood test unlock the biology of depression?

NCT ID NCT07771517

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This study investigates whether certain chemicals in the blood, called kynurenine metabolites, are linked to depressive disorders. Researchers will compare 45 people with depression to 45 healthy individuals, all aged 18 to 60. Participants will undergo psychological assessments and provide blood samples to measure these metabolites. The goal is to see if these biological markers differ between the two groups, which could help explain the biology behind depression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study finds clear differences in kynurenine metabolites, it could point toward new biomarkers for depression and possibly new treatment targets.
What could go wrong
This is a small, observational study, so it cannot prove cause and effect. Results may not apply to everyone with depression, and the findings will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2027

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with age group between 18: 60 years old and all cases are drug free of at least 4 months

Ages

18 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age group 18: 60 years old * cases are drug free of at least 4 months Exclusion Criteria: * patients with comorbid other psychiatric disorders( SUD,anxiety) * patients with IQ below 90 * patients with psychotic features * patients with postpartum depression * patients with chronic medical illness that might affect immune function * patients under treatment with immune modulating therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorders are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar disorder depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD) Major depressive disorder, bipolar disorder, other depressive disorders MDD is suspected to have the greatest burden of diseases by 2030

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.